Rezolute (RZLT) to Release Quarterly Earnings on Tuesday

Rezolute (NASDAQ:RZLT) will likely be releasing its Q3 2026 results after the market closes on Tuesday, May 12th. Analysts expect Rezolute to post earnings of ($0.1686) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Thursday, February 12th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06). On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Price Performance

RZLT traded down $0.02 on Tuesday, hitting $3.29. The company had a trading volume of 532,754 shares, compared to its average volume of 2,879,322. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.46. The stock has a fifty day simple moving average of $3.15 and a 200-day simple moving average of $4.87. The firm has a market capitalization of $314.37 million, a P/E ratio of -3.53 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Several analysts have commented on RZLT shares. Wedbush upgraded shares of Rezolute from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $2.00 to $5.00 in a report on Wednesday, March 25th. BTIG Research restated a “buy” rating and issued a $5.00 price objective on shares of Rezolute in a report on Thursday, January 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a report on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Rezolute has an average rating of “Hold” and a consensus target price of $8.00.

Hedge Funds Weigh In On Rezolute

A number of institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its holdings in Rezolute by 17.8% in the fourth quarter. Federated Hermes Inc. now owns 16,534,712 shares of the company’s stock worth $39,022,000 after purchasing an additional 2,500,000 shares in the last quarter. RA Capital Management L.P. bought a new position in Rezolute in the fourth quarter worth $21,665,000. Opaleye Management Inc. raised its holdings in Rezolute by 595.9% in the fourth quarter. Opaleye Management Inc. now owns 6,287,156 shares of the company’s stock worth $14,838,000 after purchasing an additional 5,383,714 shares in the last quarter. Balyasny Asset Management L.P. raised its holdings in Rezolute by 147.3% in the fourth quarter. Balyasny Asset Management L.P. now owns 4,506,861 shares of the company’s stock worth $10,636,000 after purchasing an additional 2,684,133 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Rezolute by 9.6% in the third quarter. Vanguard Group Inc. now owns 4,410,082 shares of the company’s stock worth $41,455,000 after purchasing an additional 387,502 shares in the last quarter. Institutional investors own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.